These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30534332)

  • 1. Efficacy of tolvaptan in a patient with right-sided heart failure and renal dysfunction refractory to diuretic therapy.
    Joko Y; Ikemura N; Miyata K; Shiraishi Y; Tanaka H; Yoshida T; Ikegami Y; Fuse J; Sakamoto M; Momiyama Y
    J Cardiol Cases; 2014 Jun; 9(6):226-229. PubMed ID: 30534332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diuretic usage for protection against end-organ damage in liver cirrhosis and heart failure.
    Mori T; Ohsaki Y; Oba-Yabana I; Ito S
    Hepatol Res; 2017 Jan; 47(1):11-22. PubMed ID: 26990144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
    Gheorghiade M; Gattis WA; O'Connor CM; Adams KF; Elkayam U; Barbagelata A; Ghali JK; Benza RL; McGrew FA; Klapholz M; Ouyang J; Orlandi C;
    JAMA; 2004 Apr; 291(16):1963-71. PubMed ID: 15113814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction.
    Hanatani A; Shibata A; Kitada R; Iwata S; Matsumura Y; Doi A; Sugioka K; Takagi M; Yoshiyama M
    Heart Vessels; 2017 Mar; 32(3):287-294. PubMed ID: 27385022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
    Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction.
    Matsue Y; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; Goldsmith SR
    J Card Fail; 2016 Jun; 22(6):423-32. PubMed ID: 26915749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of congestive heart failure with concomitant administration of tolvaptan to enhance the effects of furosemide.
    Nishizaki Y; Yamagami S; Sesoko M; Yamashita H; Daida H
    J Cardiol Cases; 2013 Nov; 8(5):151-154. PubMed ID: 30546768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.
    Uemura Y; Shibata R; Takemoto K; Uchikawa T; Koyasu M; Ishikawa S; Mitsuda T; Miura A; Imai R; Iwamiya S; Ozaki Y; Kato T; Miura T; Watarai M; Murohara T
    Heart Vessels; 2016 Oct; 31(10):1643-9. PubMed ID: 26615607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolvaptan: A Novel Diuretic in Heart Failure Management.
    Zulkifli Amin H; Suridanda Danny S
    J Tehran Heart Cent; 2016 Jan; 11(1):1-5. PubMed ID: 27403182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
    De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
    Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolvaptan alleviates excessive fluid retention of nephrotic diabetic renal failure unresponsive to furosemide.
    Takada T; Masaki T; Hoshiyama A; Toki T; Kamata Y; Shichiri M
    Nephrology (Carlton); 2018 Sep; 23(9):883-886. PubMed ID: 29665203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
    Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
    Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction.
    Matsue Y; Ter Maaten JM; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; van der Meer P; Damman K; Voors AA; Goldsmith SR
    Clin Res Cardiol; 2017 Oct; 106(10):802-812. PubMed ID: 28540483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment　- Results From the K-STAR Study.
    Inomata T; Ikeda Y; Kida K; Shibagaki Y; Sato N; Kumagai Y; Shinagawa H; Ako J; Izumi T;
    Circ J; 2017 Dec; 82(1):159-167. PubMed ID: 28835586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial clinical experience of intravenous tolvaptan sodium phosphate in patients with congestive heart failure.
    Nakamura M; Imamura T; Wakakuri E; Onoda H; Ushijima R; Kinugawa K
    J Cardiol Cases; 2023 Apr; 27(4):176-179. PubMed ID: 37012920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Impact of Tolvaptan on Intracellular and Extracellular Water in Chronic Kidney Disease Patients with Fluid Retention.
    Masuda T; Murakami T; Igarashi Y; Okabe K; Kobayashi T; Takeda SI; Saito T; Sekiguchi C; Miyazawa Y; Akimoto T; Saito O; Muto S; Nagata D
    Intern Med; 2016; 55(19):2759-2764. PubMed ID: 27725533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study).
    Matsuzaki M; Hori M; Izumi T; Fukunami M;
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S33-45. PubMed ID: 22120092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of tolvaptan on renal excretion of electrolytes and urea nitrogen in patients undergoing coronary artery bypass surgery.
    Kato TS; Nakamura H; Murata M; Kuroda K; Suzuki H; Yokoyama Y; Shimada A; Matsushita S; Yamamoto T; Amano A
    BMC Cardiovasc Disord; 2016 Sep; 16(1):181. PubMed ID: 27624603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Prospective, Multicenter, Post-Marketing Surveillance Study to Evaluate the Safety and Effectiveness of Tolvaptan in Patients with Reduced, Preserved, and Mid-Range Ejection Fraction Heart Failure.
    Kinugawa K; Sato N; Inomata T; Yasuda M; Shimakawa T; Fukuta Y
    Int Heart J; 2019 Sep; 60(5):1123-1130. PubMed ID: 31484861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.